TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: VA NEPHRON-D: Diabetes iN Nephropathy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Albuminuria \>300mg/gram creatinine~* Stage 2 or 3 CKD (eGFR 30 to \<90 mg/min/1.73m\*2 )~* Able to give informed consent~* Telephone contact available~Exclusion Criteria:~* History of intolerance to ACEI or ARB~* Serum potassium level \>5.5 meq/L~* Receiving sodium polystyrene sulfonate (Kayexalate)~* Pregnancy, breast feeding, planning to become pregnant or sexually active and not using birth control~* Renal transplant recipient~* Suspected non-diabetic kidney disease~* Inability to discontinue current use of ACEI/ARB combination~* Current use of Lithium~* Severe (end-stage) comorbid disease~* Prisoner~* Age \<18~* Estimated glomerular filtration rate (GFR) \<30 or \>=90 ml/min/1.73m\*m~* HbA1c \>10.5%~* Patient refusal~* Participation in a concurrent interventional study~* Blood pressure \>180/95~* Unwilling to stop any proscribed medications after enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of ARB and ACEI (Type: EXPERIMENTAL): Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
- Monotherapy ARB (Type: ACTIVE_COMPARATOR): Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Bupivacaine vs Peripheral Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age or older~2. Patients undergoing elective primary ankle or hindfoot surgery (ankle arthrodesis, subtalar arthrodesis, triple arthrodesis, total ankle arthroplasty, peroneal tendon debridement/transfer, Cavus Reconstruction, Medial Displacement Calcaneal Osteotomy, Dwyer Osteotomy)~Exclusion Criteria:~1. Patients who are undergoing revision surgical procedure~2. Patients who have taken opioid pain medications in the past 3 months prior to surgical procedure~3. Patients who have allergies to any of the medications or components of medications investigated in the study~4. Patients currently incarcerated~5. Patients who cannot read and speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine Group (Type: EXPERIMENTAL): No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
- Peripheral Nerve Block Group (Type: ACTIVE_COMPARATOR): Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Suspected Cases of Carbon Monoxide Poisoning in the ED

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Known or suspected carbon monoxide poisoning~Exclusion Criteria:~* Less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin for the Treatment of Postprandial Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients after bariatric surgery (i.e. sleeve gastrectomy, Roux-en-Y gastric bypass, omega- loop bypass, biliopancreatic diversion) with documented hypoglycemia, i. e. \< 3.0 mmol/l and at least 5 hypoglycemic episodes per week despite dietary modification~* For women with child-bearing potential, willingness to use contraceptive measures adequate to prevent pregnancy during the study~* Informed Consent as documented by signature~Exclusion Criteria:~* Any type of diabetes mellitus according to ADA criteria~* Intolerance to the study drug~* Signs of current infection~* Use of any drug therapy for postbariatric hypoglycemia apart from acarbose (all remaining drugs have to be discontinued four half-life times before screening phase)~* Neutropenia (leukocyte count \< 1.5 × 109/L or absolute neutrophil count (ANC) \< 0.5 × 109/L)~* Anemia (hemoglobin \< 11 g/dL for males, \< 10 g/dL for females)~* Clinically significant kidney or liver disease (creatinine \> 1.5 mg/dL, AST/ALT \> 2 × ULN, alkaline phosphatase \> 2 × ULN, or total bilirubin \[tBili\] \> 1.5 × ULN)~* Uncontrolled congestive heart failure~* Uncontrolled malignant disease~* Currently pregnant or breastfeeding~* Known or suspected non-compliance, drug or alcohol abuse~* Meeting the criteria for vulnerability (e.g. participants incapable of judgment or participants under tutelage)~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.~* Participation in another clinical trial using investigational drugs in the last 30 days or planned participation in the next 60 days~* Previous enrolment into the current study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving allogeneic peripheral blood stem cell transplant from either a related or unrelated donor at Washington University Medical Center.~* An initial episode of CMV viremia.~* At the time of randomization:~  * ANC greater than or equal to 1000~ * Age greater than or equal to 18~ * Adequate renal function with creatinine clearance greater than 10 ml/min~ * Total bilirubin less than or equal to 3.0~Exclusion Criteria:~* Current GI graft versus host disease grade III-IV~* Development of CMV disease prior to or at the time of the first detection of CMV viremia by PCR~* Uncontrolled emesis or diarrhea (greater than or equal to 4 episodes per day) for 2 consecutive days~* Pregnant or nursing female patient~* Known hypersensitivity to ganciclovir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load \>5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load \>= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is \<= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
- Group B (Type: EXPERIMENTAL): PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load \>5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load \>= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load \<= to previous viral load then 900 mg every 12 hours for another 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Either gender aged 40-75;~* Has a diagnosis of IPF, made by a respiratory expert based on International Classification of Diseases (ICD-10);~* No participation in another clinical study within 4 weeks of study start.~* Participation in this study must be voluntary and not coerced.~Exclusion Criteria:~* Have received lung transplantation.~* Any condition that may compromise patient safety.~* Pregnant women or women trying to become pregnant will be excluded from the study.~* History of drug or alcohol abuse within 6 months of study start.~* History of immunocompromise, including a positive HIV test result.~* Impaired liver and renal functions.~* Known allergies to any Chinese herbs and participants with numerous or severe allergies to any allergen.~* Pre-existing conditions including renal failure, chronic renal problems, chronic hepatitis, other pulmonary problems, diabetes, and heart problems will be excluded from the study.~* Either mentally incompetent or are unable to give informed consent because of the language barrier.~* Taking the following drugs, even as part of their current treatment regimen for IPF: pirfenidone, nintedanib, antiplatelet drugs (including aspirin, clopidogrel (Plavix), and dipyridamole (Persantine), anticoagulant drugs (including warfarin (Coumadin), enoxparin (Lovenox), and heparin), cardiac glycosides (e.g. digoxin), sedatives and sedative-containing drugs (including barbiturates, narcotic analgesics, benzodiazepines, and antihistamines), and traditional Chinese herbal medicines or granules, or other herbal medicines or supplements.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PROLUNG (Type: EXPERIMENTAL): Herbal formula treatment PROLUNG in additional to current therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects suffering from systemic sclerosis with at least an ulcerative lesion on the fingers of the upper limbs;~* The ulcer must not present bone or tendon exposure;~* Chronicity of the lesion: at least 4 weeks;~* Men and women aged ≥ 18 years;~* The patient must be able to understand the purposes of the clinical trial and provide informed consent in writing.~Exclusion Criteria:~* Patients who are participating in other clinical trials with drug or medical device;~* Patients with a history of self-harm who can voluntarily alter the course of healing;~* Women who are pregnant or breastfeeding1;~* Patients who participated in a clinical study on the healing of skin ulcers during the previous month;~* Patients who are unable to understand the purposes and objectives of the study;~* Presence of infectious signs according to IDSA criteria at the time of recruitment;~* Presence of peripheral vascular obstructive diseases;~* Patients with psychiatric disorders;~* Patients with neoplasia;~* Patients with pathologies that induce skin photosensitivity;~* Patients with a limited life expectancy.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): To the Control Group is administered the current standard therapy for 16 weeks.
- EmoLED Group (Type: EXPERIMENTAL): The treatment with EmoLED will be carried out once a week in correspondence with the dressing change of the lesion, for sixteen consecutive weeks, for a total of 16 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Patients at Risk of Chronic Back Pain Using Questionnaires

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* acute (\<6 weeks) back pain~* \>20 und \<60 years of age~* good oral and written knowledge of German language~Exclusion Criteria:~* any treatment for back pain within the last 6 months~* Cauda equina~* tumor~* generalized pain~* severe systemic illness~* substance abuse~* pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- acute back pain (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyurea in Primary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* sign written informed consent~* 18 to 60 years of age inclusive~* diagnosis of PP-MS according to McDonald criteria~* EDSS score at screening of 2-7 inclusive~Exclusion Criteria:~* hypersensitivity to hydroxyurea~* patients who were treated with immunosuppressive drugs or steroid three month before~* respiratory or urinary infections~* history or presence of malignancy~* pregnancy or lactation~* low compliance to the therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* Diagnosed by preoperative imaging modalities to have a brain tumor or vascular lesions (aneurysm, arteriovenous malformation or arteriovenous fistula) requiring surgical intervention.~* The patient is determined by a board certified Neurosurgeon (above mentioned neurosurgeons) to benefit from the application of Fluorescein Sodium intraoperatively~* Patient or legally authorized representative provides written informed consent to enroll in this study.~Exclusion Criteria:~* Known allergic reaction to Fluorescein Sodium.~* Children.~* Prisoners.~* Students.~* Infection of the central nervous system or other sites.~* Hemodynamic instability or significant impairments in circulation.~* Concomitant treatment with other investigational drugs.~* Any uncontrolled condition unrelated to the neurosurgical disease.~* History of psychiatric, additive, or any other disorder that compromises the ability to provide informed consent or comply with study protocols.~* Participation on other clinical trials during the last thirty days.~* Pregnant patients.~* Patients unable to discontinue medications that affect Fluorescein metabolism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescein Sodium (Type: EXPERIMENTAL): All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Acupuncture on the Complications of Cerebral Vascular Accident

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* first time stroke(ischemic or hemorrhagic stroke) with paresis or plegia~Exclusion Criteria:~* transient ischemic attack~* brain tumor, brain trauma~* recurrent stroke~* multiple organs failure, cancer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
- sham acupuncture (Type: SHAM_COMPARATOR): The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic and RT-PCR confirmed COVID-19 within 6 days from symptom onset.~2. Has any one of the following factors associated with disease progression:~   1. Elevated lactate dehydrogenase (LDH)~  2. Elevated C reactive protein (CRP)~  3. Lymphocyte count below normal limit~  4. Age 40 and above~  5. History of well-controlled diabetes, hypertension, chronic obstructive lung disease or ischemic heart diseases~  6. Stable chronic renal disease~  7. History of asthma~3. Disease outcome score of 6, 7 or 8 based on the COVID Scale~4. Willing to comply with the requirements of the study protocol and attend scheduled study visits~5. Can give written informed consent approved by the Ethical Review Board governing the site~Exclusion Criteria:~1. Aged below 21 years old~2. Female who is pregnant or breast-feeding~3. With the following conditions, but not limited to:~   1. Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months~  2. Child-Pugh Class C chronic liver disease~  3. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2 calculated by the CKD-EPI formula~  4. Suspected or confirmed active bacterial, fungal or mycobacterial infection~4. History of any allergic reaction to monoclonal antibodies~5. Currently enrolled in another COVID-19 investigational drug study~6. Previously enrolled in a COVID-19 investigational vaccine study~7. Any medical condition, which in the opinion of the Investigator, will compromise the safety of the patient

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- TY027 1,500 mg (Type: EXPERIMENTAL): 1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
- TY027 2,000 mg (Type: EXPERIMENTAL): 2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered via IV infusion over a period of 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues